Literature DB >> 18665196

Problems assessing uptake of Huntington disease predictive testing and a proposed solution.

Roslyn J Tassicker1, Betty Teltscher, M Kaye Trembath, Veronica Collins, Leslie J Sheffield, Edmond Chiu, Lyle Gurrin, Martin B Delatycki.   

Abstract

The uptake of predictive testing for Huntington disease informs our understanding of decision making by those at risk and assists with planning for service provision. Uptake figures have been reported from several centers based on the total number of people who have undertaken predictive testing as a percentage of those estimated to be at 50% risk in the region. This method produced a figure of 35% from our own service, much higher than observation of the local pedigrees indicated, and higher than other published reports. We have identified some errors in the commonly used formula. The major errors are the use of the cumulative total of those who have had testing with a static denominator of those at 50% risk, and the failure to exclude from the at-risk group those who are too young and therefore ineligible to test.We report data from the Huntington Disease Register of Victoria and estimate the prevalence to be 8 per 100,000 in 1999. Additional data on individuals at risk were collated. We found that for every diagnosed person there were 4.2 individuals at 50% risk, a lower ratio than one to five hypothesized in the literature. We examined these ratios in the context of uptake.Significantly, we provide a solution to the calculation of uptake with a formula that factors in a dynamic denominator and corrects for the number of years testing has been offered. Using this formula, we calculated an uptake of 13.0-15.4% for the state of Victoria, Australia. This formula can be used to compare uptake across different centers.

Entities:  

Mesh:

Year:  2008        PMID: 18665196      PMCID: PMC2985957          DOI: 10.1038/ejhg.2008.142

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  15 in total

1.  Predictive testing for Huntington's disease: a universal model?

Authors:  Michael R Hayden
Journal:  Lancet Neurol       Date:  2003-03       Impact factor: 44.182

2.  Uptake of presymptomatic predictive testing for Huntington's disease.

Authors:  D Craufurd; A Dodge; L Kerzin-Storrar; R Harris
Journal:  Lancet       Date:  1989-09-09       Impact factor: 79.321

3.  Presymptomatic testing in Huntington's disease and autosomal dominant cerebellar ataxias.

Authors:  C Goizet; G Lesca; A Dürr
Journal:  Neurology       Date:  2002-11-12       Impact factor: 9.910

4.  Ten years of presymptomatic testing for Huntington's disease: the experience of the UK Huntington's Disease Prediction Consortium.

Authors:  P S Harper; C Lim; D Craufurd
Journal:  J Med Genet       Date:  2000-08       Impact factor: 6.318

5.  DNA analysis of Huntington's disease: five years of experience in Germany, Austria, and Switzerland.

Authors:  F Laccone; U Engel; E Holinski-Feder; M Weigell-Weber; K Marczinek; D Nolte; D J Morris-Rosendahl; C Zühlke; K Fuchs; H Weirich-Schwaiger; G Schlüter; G von Beust; A M Vieira-Saecker; B H Weber; O Riess
Journal:  Neurology       Date:  1999-09-11       Impact factor: 9.910

6.  Paradox of a better test for Huntington's disease.

Authors:  A Maat-Kievit; M Vegter-van der Vlis; M Zoeteweij; M Losekoot; A van Haeringen; R Roos
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-11       Impact factor: 10.154

Review 7.  Huntington disease: genetics and epidemiology.

Authors:  P M Conneally
Journal:  Am J Hum Genet       Date:  1984-05       Impact factor: 11.025

8.  Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000.

Authors:  S Creighton; E W Almqvist; D MacGregor; B Fernandez; H Hogg; J Beis; J P Welch; C Riddell; R Lokkesmoe; M Khalifa; J MacKenzie; A Sajoo; S Farrell; F Robert; A Shugar; A Summers; W Meschino; D Allingham-Hawkins; T Chiu; A Hunter; J Allanson; H Hare; J Schween; L Collins; S Sanders; C Greenberg; S Cardwell; E Lemire; P MacLeod; M R Hayden
Journal:  Clin Genet       Date:  2003-06       Impact factor: 4.438

9.  Predictive testing for Huntington disease: II. Demographic characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates.

Authors:  M Bloch; M Fahy; S Fox; M R Hayden
Journal:  Am J Med Genet       Date:  1989-02

10.  Fifteen years of experience in predictive testing for Huntington disease at a single testing center in Victoria, Australia.

Authors:  M Kaye Trembath; Roslyn J Tassicker; Veronica R Collins; Sue Mansie; Leslie J Sheffield; Martin B Delatycki
Journal:  Genet Med       Date:  2006-11       Impact factor: 8.822

View more
  17 in total

1.  Preimplantation genetic diagnosis (PGD) for Huntington's disease: the experience of three European centres.

Authors:  Maartje C Van Rij; Marjan De Rademaeker; Céline Moutou; Jos C F M Dreesen; Martine De Rycke; Inge Liebaers; Joep P M Geraedts; Christine E M De Die-Smulders; Stéphane Viville
Journal:  Eur J Hum Genet       Date:  2011-11-09       Impact factor: 4.246

2.  Presymptomatic testing of those at 25% risk of autosomal dominant neurodegenerative disease- testing team beware.

Authors:  Martin B Delatycki
Journal:  Eur J Hum Genet       Date:  2018-10-05       Impact factor: 4.246

3.  CAG repeat size in Huntingtin alleles is associated with cancer prognosis.

Authors:  Morgane Sonia Thion; Sophie Tézenas du Montcel; Jean-Louis Golmard; Sophie Vacher; Laure Barjhoux; Valérie Sornin; Cécile Cazeneuve; Ivan Bièche; Olga Sinilnikova; Dominique Stoppa-Lyonnet; Alexandra Durr; Sandrine Humbert
Journal:  Eur J Hum Genet       Date:  2016-03-16       Impact factor: 4.246

4.  22 Years of predictive testing for Huntington's disease: the experience of the UK Huntington's Prediction Consortium.

Authors:  Sheharyar S Baig; Mark Strong; Elisabeth Rosser; Nicola V Taverner; Ruth Glew; Zosia Miedzybrodzka; Angus Clarke; David Craufurd; Oliver W Quarrell
Journal:  Eur J Hum Genet       Date:  2016-05-11       Impact factor: 4.246

5.  The Spectrum of Caregiving in Palliative Care for Serious, Advanced, Rare Diseases: Key Issues and Research Directions.

Authors:  Lynn S Adams; Jeri L Miller; Patricia A Grady
Journal:  J Palliat Med       Date:  2016-06-01       Impact factor: 2.947

6.  Prenatal Testing for Adult-Onset Conditions: the Position of the National Society of Genetic Counselors.

Authors:  Laura Hercher; Wendy R Uhlmann; Erin P Hoffman; Shanna Gustafson; Kelly M Chen
Journal:  J Genet Couns       Date:  2016-07-01       Impact factor: 2.537

Review 7.  Ethical issues in neurogenetics.

Authors:  Wendy R Uhlmann; J Scott Roberts
Journal:  Handb Clin Neurol       Date:  2018

8.  Prenatal testing in Huntington disease: after the test, choices recommence.

Authors:  Hanane Bouchghoul; Stéphane-Françoise Clément; Danièle Vauthier; Cécile Cazeneuve; Sandrine Noel; Marc Dommergues; Delphine Héron; Jacky Nizard; Marcela Gargiulo; Alexandra Durr
Journal:  Eur J Hum Genet       Date:  2016-06-15       Impact factor: 4.246

9.  Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study.

Authors:  Eric A Epping; James A Mills; Leigh J Beglinger; Jess G Fiedorowicz; David Craufurd; Megan M Smith; Mark Groves; Kelly R Bijanki; Nancy Downing; Janet K Williams; Jeffrey D Long; Jane S Paulsen
Journal:  J Psychiatr Res       Date:  2013-06-19       Impact factor: 4.791

10.  Everyday cognition in prodromal Huntington disease.

Authors:  Janet K Williams; Ji-In Kim; Nancy Downing; Sarah Farias; Deborah L Harrington; Jeffrey D Long; James A Mills; Jane S Paulsen
Journal:  Neuropsychology       Date:  2014-07-07       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.